Methods: Between January 2000 and February 2003, 138 patients recieved bileaflet [(St. Jude (39), Sorin Bicarbon (41), TRI (22)] or monoleaflet [Omnicarbon (17), Bjork-Shiley (19)] mechanical mitral prostheses in Van Yüksek Ihtisas Hospital.
Results: The operative mortality (4.9% versus 5.5%, respectively) and late mortality (7.2% versus 8.8%, respectively) in bileaflet and monoleaflet groups were not significantly different. The incidences of thrombotic occlusion were 5.5%, 0%, 26.3%, 6.2%, 16.6% for St. Jude, Sorin, TRI, Omnicarbon and Bjork-Shiley, respectively. Thrombolytic treatment was given to six patients [Bileaflet (3), Monoleaflet (3)], and urgent re-operation was performed in five patients [Bileaflet (2), Monoleaflet (3)]. The mortality rates of prosthetic valve thrombosis were 2.7%, 0%, 15.7%, 0%, 11.1% for St. Jude, Sorin, TRI, Omnicarbon and Bjork-Shiley, respectively.
Conclusion: This study suggest that the thrombotic and thromboembolic incidence of TRI and Bjork-Shiley prostheses are significantly higher than the other three prostheses for postoperative 1.4 ± 0.6 year period (p < 0.01).